<img alt="" height="1" width="1" />Astellas buys Japan, other rights to new IBS drugè·¯é€ä¸å›½Astellas will pay $75 million upfront to develop linaclotide, now in Phase III trials in the United States to treat irritable bowel syndrome with ...<nobr></nobr> |